Maker of coronavirus trial drug aims for wide distribution - Gilead CEO [Reuters]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Reuters
Maker of coronavirus trial drug aims for wide distribution - Gilead CEO (Reuters) - Gilead Sciences ( GILD.O ), which manufactures remdesivir, is focused on making the experimental coronavirus drug accessible and affordable to as many people as possible once it is approved, Chief Executive Officer Daniel O’Day said on Friday. Interest in remdesivir has been high as there are no approved treatments or preventive vaccines yet for COVID-19, and early U.S. government trial results on Wednesday showed the drug helped patients recover more quickly from the illness caused by the new coronavirus than patients given a placebo. Gilead has already said it will donate the first 1.5 million doses of remdesivir and O’Day told NBC’s “Today” show that the company understood its responsibility to make a difference during the coronavirus pandemic. “I can assure you that we’re all focused on making sure that we make this accessible and affordable to patients around the globe,” he said. He said there h
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead (GILD) Valuation After Fresh Buy Rating and Extended Biktarvy Exclusivity Boost Investor Confidence [Yahoo! Finance]Yahoo! Finance
- Madonna pens scathing post against Trump for 'unthinkable' decision to ignore World AIDS Day [FOX News]FOX News
- Mableton man uses TikTok to fight HIV stigma as federal government skips World AIDS Day recognition [CBS News]CBS News
- Elton John reveals what would make Trump one of the 'greatest presidents' in history [FOX News]FOX News
- National AIDS Memorial Marks World AIDS Day with Two Signature Events Highlighting the Power of Communities to Shape Progress in the Fight Against HIV/AIDS and Advance Health and Social Justice [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 10/30/25 - Beat
GILD
Sec Filings
- 12/1/25 - Form 4
- 12/1/25 - Form 4
- 12/1/25 - Form 4
- GILD's page on the SEC website